Answers are grounded in this paper and cite their sources.
Cohort study reports reduced severe hypophosphatemia and phosphate needs in ALF patients using Phoxilium, suggesting improved management during continuous renal replacement therapy.
Hypophosphatemia is common in Acute Liver Failure (ALF) and may worsen during continuous renal replacement therapy (CRRT) with phosphate-free fluids. We aimed to evaluate the safety and efficacy of Phoxilium®, a phosphate-containing CRRT fluid. We conducted a retrospective single-centre cohort study of paracetamol-induced ALF patients treated with CRRT between as our ICU transitioned from Accusol® to Phoxilium®. We obtained data on demographics, biochemistry, and outcomes. We compared biochemical variables every 6 hours up to 48 hours post-CRRT initiation and then every 12 hours until 168 hours. The primary outcome was the occurrence of severe hypophosphatemia (< 0.32 mmol/L). In 38 ALF patients (Phoxilium®=14 and Accusol®=24). Phoxilium® was associated with elimination of severe hypophosphatemia (0% vs. 38%; p=0.014), a reduction in its median burden (proportion of phosphate readings < 0.81 mmol/L: 13% [IQR; 2-33%] vs. 44% [29-51%]; p=0.001), and significantly lower phosphate supplementation requirements (median, 45 mmol [20-70 mmol] vs. 100 mmol [60-210 mmol]; p=0.008). Phoxilium® patients experienced a small but significant decrease in median arterial pH and standard base excess, which remained within normal limits, but lower than with Accusol® (p = 0.018 and p = 0.046, respectively). No significant differences were observed in clinical outcomes. In paracetamol-induced ALF patients, Phoxilium® was associated with reduced incidence of severe hypophosphatemia, hypophosphatemia burden, and need of phosphate supplementation. Larger studies are needed to further assess its impact on ALF patient outcomes.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: